Top ▲

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

CD19

Click here for help

Target id: 2764

Nomenclature: CD19

Family: CD molecules

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 556 16p11.2 CD19 CD19 molecule 4
Mouse 1 547 7 69.01 cM Cd19 CD19 antigen 4
Rat - 547 1q36 Cd19 CD19 molecule
Database Links Click here for help
Alphafold P15391 (Hs), P25918 (Mm)
CATH/Gene3D 2.60.40.10
ChEMBL Target CHEMBL3390821 (Hs)
Ensembl Gene ENSG00000177455 (Hs), ENSMUSG00000030724 (Mm), ENSRNOG00000018311 (Rn)
Entrez Gene 930 (Hs), 12478 (Mm), 365367 (Rn)
Human Protein Atlas ENSG00000177455 (Hs)
KEGG Gene hsa:930 (Hs), mmu:12478 (Mm), rno:365367 (Rn)
OMIM 107265 (Hs)
Pharos P15391 (Hs)
RefSeq Nucleotide NM_001178098 (Hs), NM_009844 (Mm), NM_001013237 (Rn)
RefSeq Protein NP_001171569 (Hs), NP_033974 (Mm), NP_001013255 (Rn)
UniProtKB P15391 (Hs), P25918 (Mm)
Wikipedia CD19 (Hs)

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
inebilizumab Peptide Approved drug Primary target of this compound Hs Binding 9.3 – 10.3 pKd 1
⤷ pKd 9.3 – 10.3 (Kd 5x10-10 – 5x10-11 M) [1]
blinatumomab Peptide Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Binding 9.0 pKd 2
⤷ pKd 9.0 (Kd 1x10-9 M) [2]
Description: Binding of the single-chain Fv portion of blinatumomab to CD19.
tafasitamab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding - - 3
⤷ [3]
loncastuximab tesirine Peptide Approved drug Hs Binding - - 5
⤷ [5]
Antibody Comments
A CD19-targeting ADC was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR: ABBV-319 is an anti-CD19 antibody with a potent glucocorticosteroid payload, that was developed for potential to treat B-cell malignancies (phase 1 NCT05512390). It is proposed to deliver anticancer activity, whilst minimising the risk of systemic steroid toxicities (by selectively targeting to CD19 +ve cells), and promotes enhanced antibody-dependent cellular cytotoxicity (ADCC) as a result of afucosylation of its Fc region.
Immunopharmacology Comments
CD19 is a B cell antigen used as a biomarker for normal and neoplastic B cells, and follicular dendritic cells. Anti-CD19 monoclonal antibodies are being investigated for potential clinical utility in oncology, transplantation and autimmune diseases (e.g. inebilizumab). Blinatumomab is a bispecific CD19/CD3e mAb already approved as a treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.
Cell Type Associations
Immuno Cell Type:  B cells
Cell Ontology Term:   B cell (CL:0000236)
Immuno Disease Associations
Disease Name:  Acute lymphocytic leukemia (ALL)
Disease Synonyms:  no synonyms
Comment:  CD19 is one of the molecular targets of the bi-specific antibody drug blinatumomab (also binds CD3e).
Disease X-refs:  OMIM: 613065
References: 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Immunodeficiency, common variable, 3; CVID3
Synonyms: Common variable immunodeficiency [Orphanet: ORPHA1572] [Disease Ontology: DOID:12177]
Disease Ontology: DOID:12177
OMIM: 613493
Orphanet: ORPHA1572

References

Show »

1. Damschroder M, Kiener P, Wu H, Dall'Acqua W, Herbst R, Coyle A. (2012) Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Patent number: US8323653 B2. Assignee: Medimmune, Llc. Priority date: 08/09/2006. Publication date: 04/12/2012.

2. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer, 100 (6): 690-7. [PMID:12209608]

3. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R et al.. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res, 68 (19): 8049-57. [PMID:18829563]

4. Tedder TF, Isaacs CM. (1989) Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol, 143 (2): 712-7. [PMID:2472450]

5. Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S et al.. (2018) ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood, 131 (10): 1094-1105. [PMID:29298756]

How to cite this page

CD molecules: CD19. Last modified on 20/04/2023. Accessed on 28/10/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2764.